Next Article in Journal
9-Aminoquino[2',3':3,4]pyrrolo[2,1-b]quinazolin-11(13H)-one
Previous Article in Journal
N1-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

(S)-Ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate

by
Giovanni Lentini
,
Maria Maddalena Cavalluzzi
*,
Leonardo Degennaro
,
Giuseppe Fracchiolla
,
Filippo Perna
and
Antonio Scilimati
*
Department of Pharmacy - Pharmaceutical Sciences, University of Bari, Via E. Orabona 4, 70126 Bari, Italy
*
Authors to whom correspondence should be addressed.
Molbank 2019, 2019(1), M1049; https://doi.org/10.3390/M1049
Submission received: 18 January 2019 / Revised: 15 February 2019 / Accepted: 18 February 2019 / Published: 21 February 2019
(This article belongs to the Section Organic Synthesis)

Abstract

:
A multistep gram-scale synthesis of (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate (2) has been developed. The title compound was prepared starting from commercially available l-DOPA which was O- and N-protected before undergoing iodination by CF3CO2Ag/I2. The structure of the target compound was confirmed using IR, 1H-NMR, 13C-NMR, 2D (COSY, HSQC) NMR spectroscopy, as well as ESI-MS and HRMS.

Graphical Abstract

1. Introduction

3,4-Dihydroxy-6-[18F]fluoro-l-phenylalanine—6-[18F]fluoro-l-DOPA or 6-[18F]fluoro levodopa (1, Figure 1)—is a positron emission tomography (PET) diagnostic radiotracer [1,2], useful to detect pathological loss of dopaminergic neuron terminals in the striatum. Thus, 6-[18F]fluoro-l-DOPA is used for the diagnosis of Parkinson′s disease (PD) and distinction between essential tremor and parkinsonian syndromes (PS), especially at the PS onset [3]. 6-[18F]Fluoro-l-DOPA is also useful to detect tumors with an increase intracellular transport and decarboxylation of l-DOPA. In fact, 6-[18F]fluoro-l-DOPA has a privileged role in the diagnosis of pheochromocytoma, paraganglioma, and brain tumors [4]. Other possible applications include psychiatric [5,6] and age-related neurodegenerative disorder diagnoses [7].
Several synthetic routes to 1 have been reported in the literature [8,9,10,11,12,13,14,15,16]. However, most of them suffer from limitations such as the formation of regioisomers as reaction by-products, long reaction times, and low overall yield. Thus, herein we report on the synthesis and structural identification of an intermediate suitable for a gram-scalable nucleophilic fluorination of levodopa.

2. Results and Discussion

The synthesis of (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate (2, Scheme 1) was performed starting from commercially available levodopa which was reacted with thionyl chloride in EtOH to give the corresponding ethyl ester, whose amino group was in turn protected by BOC. The protection of catechol hydroxyl groups with CH2I2 in the presence of Cs2CO3 gave the benzodioxole derivative 3 (see Scheme 1) which was in turn submitted to an iodination reaction at the C-6 position. A similar synthetic strategy was previously reported in a Chinese patent [17] where the iodination step was performed using PhI(O2CCF3)2/I2. We chose CF3CO2Ag/I2 [18] as the iodinating reagent since it is cheaper and more atom efficient than PhI(O2CCF3)2/I2. Furthermore, CF3CO2Ag/I2 should allow easier product purification since the chosen iodination promoter does not liberate iodobenzene in the reaction crude. Finally, the reaction time was reduced from overnight to 15 minutes in our conditions, nevertheless ensuring a comparable yield (73%, 70% [17]).
Through a procedure recently proposed for the synthesis of [18F]labeled compounds for PET imaging [19], a copper-mediated nucleophilic fluorination of 2 could be carried out. In order to avoid a possible hydro-dehalogenation caused by the relatively acidic NH carbamate proton, the Boc-derivative of 2 should be synthesized should be previously synthesized (Scheme 2).
The structure of the synthesized compound 2 has been confirmed using NMR spectroscopy and mass spectrometry. Likely as a consequence of a hindered rotation around some Csp3–Csp3 and Csp3–Csp2 bonds, a mixture of rotamers of 2 in 1H and 13C-NMR spectra were recorded in CDCl3. A variable-temperature 1H-NMR study in CD3OD was then performed in the range of temperature 25–50 °C. In particular, at 50 °C a coalescence of signals occurred allowing more sharp and detectable signals (see 1H-NMR spectra in Figures S3, S5). On the basis of homonuclear (COSY) and heteronuclear (HSQC) experiments, it was possible to assign all 1H and 13C chemical shifts of 2 (see Figures S8, S9). The 1H and 13C-NMR spectra recorded in CD3OD at 50 °C will be described.

3. Materials and Methods

3.1. General Information

Unless otherwise specified, yields refer to purified products and were not optimized. The structures of the compounds were confirmed using routine spectrometric analyses. Only spectra for compounds never previously described, to our knowledge, are given. Compounds used as starting materials were purchased from either Aldrich (Chemical Co., Milwaukee, WI, USA) or Lancaster (Synthesis, Inc., Frankfurt, Germany) and were used without any further purification. Solvents were RP grade, unless otherwise indicated. 1H 500-MHz and 13C 125-MHz spectra were recorded on an Agilent 500-vnmrs500 spectrometer (Agilent Technologies, Palo Alto, CA, USA). Chemical shifts are reported in ppm using solvent resonance [(residual non-deuterated solvent for 1H-NMR): CD3OD, δ 3.30 (1H-NMR) and δ 47.8 (13C-NMR)] as reference. J absolute values are given in Hz. ESI+/−/MS/MS analyses were performed with an Agilent 1100 series LC-MSD trap system VL Workstation (Agilent Technologies, Palo Alto, CA, USA). HRMS analyses were performed using a Bruker microTOF QII mass spectrometer (Bruker, Bremen, Germany) equipped with ESI operating in positive ion mode. The IR were recorded on a Perkin-Elmer Spectrum One FT spectrophotometer (Perkin Elmer Corporation, Norwalk, CT, USA) and band positions are given in reciprocal centimeters (cm−1). Eluting solvent, to isolate the product, is indicated in parentheses and was determined using TLC, performed on precoated silica gel on aluminum sheets (Kieselgel 60 F254, Merck, Darmstadt, Germany). TLC plates were visualized with UV light and/or in an iodine chamber. Column chromatography was performed on ICN silica gel 60 Å (63–200 µm) as a stationary phase. The weight of the silica gel was approximately 100 times that of the substance.

3.2. (S)-Ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate (2)

CF3COOAg (0.67 g, 3.05 mmol) and I2 (0.78 g, 3.05 mmol) were added to a solution of 3 (0.79 g, 2.34 mmol) in CH2Cl2 (28 mL) at −5 °C. After stirring at −5 °C for 15 min, the resulting AgI precipitate was filtered and the filtrate was washed with saturated aqueous Na2S2O3 solution. The organic layer was dried (Na2SO4) and evaporated under reduced pressure affording 0.99 g of a yellowish oil which was purified through column chromatography (EtOAc/hexane 2:8) which gave 0.79 g (73%) of the desired product as a colorless oil: [ α ] D 20 = +103 (c 1, EtOH); 1H-NMR (CD3OD, 50 °C): δ 1.24 (t, J = 7.0 Hz, 3H, CH3), 1.38 (s, 9H, t-Bu), 2.92 (t, J = 11.0 Hz, CHH), 3.20 (dd, J = 14.1, 5.9 Hz, 1H, CHH), 4.16 (q, J = 7.0 Hz, 2H, CH2CH3), 4.39 (dd, J = 9.1, 5.9 Hz, 1H, CH), 5.89–5.96 (m, 2H, OCH2O), 6.79 (s, 1H, ArH), 7.24 (s, 1H, ArH); 13C-NMR [attached proton test (APT), CD3OD, 50 °C] δ 13.0 (OCH2CH3), 27.2 (3 x CH3), 42.0 (CHCH2), 53.9 (CHCH2), 60.9 (OCH2CH3), 79.3 (C(CH3)3), 87.5 (CArI), 101.7 (OCH2O), 110.2 (HCAr), 118.1 (HCAr), 133.1 (CAr), 147.6 (OCAr), 148.5 (OCAr), 154.7 (NHC=O), 172.0 (OC=O); FT-IR (neat, cm−1): 3392, 2977, 2917, 1795, 1707, 1475, 1390, 1228, 1162, 1036, 931, 858; ESI+/MS m/z 486 [M + Na]+; ESI+/MS/MS m/z 386 (100); HRMS [direct analysis in real time (DART), m/z] Calcd. for C17H22INO6: 486.0384 ([M + Na]+); found: 486.0379.

4. Conclusions

In conclusion, (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate (2) has been successfully synthesized starting from commercially available l-DOPA and using CF3CO2Ag/I2 as the iodinating reagent. The title compound is a suitable intermediate for the synthesis of 6-fluoro-l-DOPA and certain derivatives by cross-coupling reactions.

Supplementary Materials

1H and 13C-NMR spectra of compounds 2 and 3 are available online.

Author Contributions

Conceptualization, G.L. and A.S.; writing—original draft preparation, G.L. and M.M.C.; writing—review, M.M.C.; synthesis of the intermediate 3, G.F.; synthesis of the target compound, M.M.C. and L.D.; spectral data, L.D. and F.P.; supervision and project administration, A.S. All authors read and approved the final manuscript.

Funding

The project was supported by a grant from the Italian Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) under the project entitled "Research, Application, Innovation, Services in Bioimaging (R.A.I.S.E. in Bioimaging), code PON01_03054.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Denora, N.; Lopedota, A.; de Candia, M.; Cellamare, S.; Degennaro, L.; Luisi, R.; Mele, A.; Tricarico, D.; Cutrignelli, A.; Laquintana, V.; et al. Pharmaceutical development of novel lactate-based 6-fluoro-l-DOPA formulations. Eur. J. Pharmac. Sci. 2017, 99, 361–368. [Google Scholar] [CrossRef]
  2. Trapani, A.; Tricarico, D.; Mele, A.; Maqoud, F.; Mandracchia, D.; Vitale, P.; Capriati, V.; Trapani, G.; Dimiccoli, V.; Tolomeo, A.; et al. A novel injectable formulation of 6-fluoro-l-DOPA imaging agent for diagnosis of neuroendocrine tumors and Parkinson’s disease. Int. J. Pharmac. 2017, 519, 304–313. [Google Scholar] [CrossRef]
  3. Seibyl, J.P.; Chen, W.; Silverman, D.H.S. 3,4-Dihydroxy-6-[18F]-fluoro-l-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin. Nucl. Med. 2007, 37, 440–450. [Google Scholar] [CrossRef] [PubMed]
  4. Lussey-Lepoutre, C.; Hindié, E.; Montravers, F.; Detour, J.; Ribeiro, M.-J.S.; Taïeb, D.; Imperiale, A. The current role of 18F-FDOPA PET for neuroendocrine tumor imaging. Med. Nucl. 2016, 40, 20–30. [Google Scholar] [CrossRef]
  5. Laakso, A.; Wallius, E.; Kajander, J.; Bergman, J.; Eskola, O.; Solin, O.; Ilonen, T.; Salokangas, R.K.R.; Syvälahti, E.; Hietala, J. Personality Traits and Striatal Dopamine Synthesis Capacity in Healthy Subjects. Am. J. Psychiatry 2003, 160, 904–910. [Google Scholar] [CrossRef] [PubMed]
  6. McGowan, S.; Lawrence, A.D.; Sales, T.; Quested, D.; Grasby, P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch. Gen. Psychiatry 2004, 61, 134–142. [Google Scholar] [CrossRef] [PubMed]
  7. Van Brocklin, H.F. Radiopharmaceuticals for drug development: Unites States regulatory perspective. Curr. Radiopharm. 2008, 1, 2–6. [Google Scholar] [CrossRef]
  8. Cole, E.L.; Stewart, M.N.; Littich, R.; Hoareau, R.; Scott, J.H. Radiosyntheses using fluorine-18: The art and science of late stage fluorination. Curr. Top. Med. Chem. 2014, 14, 875–900. [Google Scholar] [CrossRef] [PubMed]
  9. Coenen, H.H.; Ermert, J. Direct nucleophilic 18F-fluorination of electron-rich arenes: Present limits of no-carrier-added reactions. Curr. Radiopharm. 2010, 3, 163–173. [Google Scholar] [CrossRef]
  10. Tredwell, M.; Gouverneur, V. 18F labeling of arenes. Angew. Chem. Int. Ed. 2012, 51, 11426–11437. [Google Scholar] [CrossRef] [PubMed]
  11. Pimlott, S.L.; Sutherland, A. Molecular tracers for the PET and SPECT imaging of disease. Chem. Soc. Rev. 2011, 40, 149–162. [Google Scholar] [CrossRef] [PubMed]
  12. Chaly, T.; Diksic, M. High yield synthesis of 6-[18F]fluoro-l-Dopa by regioselective fluorination of protected l-Dopa with [18F]acetylhypofluorite. J. Nucl. Med. 1986, 27, 1896–1901. [Google Scholar] [PubMed]
  13. Edwards, R.; Wirth, T. [18F]6-Fluoro-3,4-dihydroxy-l-phenylalanine–recent modern syntheses for an elusive radiotracer. J. Label. Compd. Radiopharm. 2015, 58, 183–187. [Google Scholar] [CrossRef] [PubMed]
  14. Ichiishi, N.; Brooks, A.F.; Topczewski, J.J.; Rodnick, M.E.; Sanford, M.S.; Scott, P.J.H. Copper-catalyzed [18F]fluorination of (mesityl)(aryl)iodonium salts. Org. Lett. 2014, 16, 3224–3227. [Google Scholar] [CrossRef] [PubMed]
  15. Makaravage, K.J.; Brooks, A.F.; Mossine, A.V.; Sanford, M.S.; Scott, P.J.H. Copper-mediated radiofluorination of arylstannanaes with [18F]KF. Org. Lett. 2016, 18, 5440–5443. [Google Scholar] [CrossRef]
  16. Tredwell, M.; Preshlock, S.M.; Taylor, N.J.; Gruber, S.; Huiban, M.; Passchier, J.; Mercier, J.; Génicot, C.; Gouverneur, V. A general copper-mediated nucleophilic 18F fluorination of arenes. Angew. Chem. Int. Ed. Engl. 2014, 53, 7751–7755. [Google Scholar] [CrossRef]
  17. Wang, L.; Zheng, C. Novel Preparation Method for Positron Medicine [18F]FDOPA and Intermediate Thereof. CN 107311877A, 3 November 2017. [Google Scholar]
  18. Chouhan, G.; Alper, H. Palladium-catalyzed carboxamidation reaction and aldol condensation reaction cascade: A facile approach to ring-fused isoquinolinones. Org. Lett. 2008, 10, 4987–4990. [Google Scholar] [CrossRef] [PubMed]
  19. Fier, P.S.; Hartwig, J.F. Copper-Mediated Fluorination of Aryl Iodides. J. Am. Chem. Soc. 2012, 134, 10795–10798. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Figure 1. 6-[18F]Fluoro levodopa (1) and (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate (2).
Figure 1. 6-[18F]Fluoro levodopa (1) and (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate (2).
Molbank 2019 m1049 g001
Scheme 1. Preparation of (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5 methylenedioxyphenyl)propanoate (2).
Scheme 1. Preparation of (S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5 methylenedioxyphenyl)propanoate (2).
Molbank 2019 m1049 sch001
Scheme 2. Copper-mediated fluorination of 2.
Scheme 2. Copper-mediated fluorination of 2.
Molbank 2019 m1049 sch002

Share and Cite

MDPI and ACS Style

Lentini, G.; Cavalluzzi, M.M.; Degennaro, L.; Fracchiolla, G.; Perna, F.; Scilimati, A. (S)-Ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate. Molbank 2019, 2019, M1049. https://doi.org/10.3390/M1049

AMA Style

Lentini G, Cavalluzzi MM, Degennaro L, Fracchiolla G, Perna F, Scilimati A. (S)-Ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate. Molbank. 2019; 2019(1):M1049. https://doi.org/10.3390/M1049

Chicago/Turabian Style

Lentini, Giovanni, Maria Maddalena Cavalluzzi, Leonardo Degennaro, Giuseppe Fracchiolla, Filippo Perna, and Antonio Scilimati. 2019. "(S)-Ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate" Molbank 2019, no. 1: M1049. https://doi.org/10.3390/M1049

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop